Eli Lilly reported second quarter 2026 revenue of $23.0 billion, up 48% year-over-year, and reported EPS of $7.94. The results were driven by strong demand for Mounjaro and Zepbound, leading the company to raise its full-year 2026 revenue guidance.
Key Highlights
- Lilly raised its full-year 2026 revenue guidance to a new range of $85.0 billion to $87.0 billion, from a prior $82 billion to $85 billion.
- Second quarter revenue growth of 48% was driven by a 60% increase in worldwide volume, primarily from Mounjaro and Zepbound, partially offset by a 13% decrease in realized prices.
- Combined worldwide revenue for Mounjaro ($9.9 billion) and Zepbound ($4.9 billion) reached nearly $14.9 billion for the quarter.